EGFR-IN-8

CAS No. 2407957-87-1

EGFR-IN-8( —— )

Catalog No. M26192 CAS No. 2407957-87-1

EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 259 Get Quote
10MG 430 Get Quote
25MG 710 Get Quote
50MG 972 Get Quote
100MG 1332 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    EGFR-IN-8
  • Note
    Research use only, not for human use.
  • Brief Description
    EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.
  • Description
    EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.(In Vitro):In A549, PC9, H1975, CL68, and CL97?cells, EGFR-IN-8 (0-0.6 μM; 48 hours) suppresses the expression of EGFR and c-Met in these five cell lines irrespective of their mutational status. EGFR-IN-8 (0-20 μM; 24, 48, 72 hours) exhibits a time- and dose-dependent inhibitory effect on the viability of A549, PC9, H1975, CL68, and CL97?cells at different time intervals, with IC50 values ranging from 0.3 to 0.6?μM and 0.2-0.5?μM after 48 and 72?h of treatment respectively.(In Vivo):EGFR-IN-8 (50,150?mg/kg; oral gavage) exhibits suppression (29% and 60%, respectively) of H1975 xenograft tumor growth in a dose-dependent manner.
  • In Vitro
    EGFR-IN-8 (0-20 μM; 24-72 hours) exhibits a time- and dose-dependent inhibitory effect on the viability of A549, PC9, H1975, CL68, and CL97?cells at different time intervals, with IC50 values ranging from 0.3 to 0.6?μM and 0.2-0.5?μM after 48 and 72?h of treatment respectively. EGFR-IN-8 (0-0.6 μM; 48 hours) suppresses the expression of EGFR and c-Met in these five cell lines irrespective of their mutational status. Cell Viability Assay Cell Line:A549, PC9, H1975, CL68, and CL97?cells Concentration:0-20 μM Incubation Time:24 hours, 48 hours, 72 hours Result:Showed inhibitory effects on different cells.Western Blot Analysis Cell Line:A549, PC9, H1975, CL68, and CL97?cells Concentration:0-0.6 μM Incubation Time:48 hours Result:Decreased EGFR and c-Met expression.
  • In Vivo
    EGFR-IN-8 (oral gavage; 50 and 150?mg/kg; once daily; 20 days) exhibits a dose-dependent suppression (29% and 60%, respectively) of H1975 xenograft tumor growth at 50 and 150?mg/kg. Animal Model:Nude mice H1975 xenograft tumor model Dosage:50 and 150?mg/kg Administration:Oral gavage; 50 and 150?mg/kg; once daily; 20 days Result:Inhibited H1975 xenograft tumor growth.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2407957-87-1
  • Formula Weight
    662.03
  • Molecular Formula
    C32H23ClF3N7O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 8.33 mg/mL (12.58 mM)
  • SMILES
    FC(F)(F)c1cc(NC(=O)Nc2cccc(c2)-c2nc(no2)-c2ccc(NC(=O)c3cccnc3)cc2Cl)ccc1NC(=O)C1CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Chandoga J, et al. Cetaben and fibrates both influence the activities of peroxisomal enzymes in different ways. Biochem Pharmacol. 1994 Feb 9;47(3):515-9.
molnova catalog
related products
  • WHI-P258

    WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3.

  • AEE-788

    A potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively.

  • Alflutinib methanesu...

    Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.